Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Antitumor activity of solamargine in mouse melanoma model: relevance to clinical safety

Texto completo
Autor(es):
Furtado, Ricardo Andrade [1] ; Ozelin, Saulo Duarte [1] ; Ferreira, Natalia Helen [1] ; Miura, Barbara Ayumi [1] ; Almeida Junior, Silvio [1] ; Magalhaes, Georgia Mode [1] ; Nassar, Eduardo Jose [1] ; Miranda, Mariza Abreu [2] ; Bastos, Jairo Kenupp [2] ; Tavares, Denise Crispim [1]
Número total de Autores: 10
Afiliação do(s) autor(es):
[1] Univ Franca, Ave Dr Armando Salles Oliveira, 201 Parque Univ, BR-14404600 Franca, SP - Brazil
[2] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Sao Paulo, SP - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES; v. 85, n. 4 OCT 2021.
Citações Web of Science: 0
Resumo

Melanoma is the most aggressive type of skin cancer, and thus it is important to develop new drugs for its treatment. The present study aimed to examine the antitumor effects of solamargine a major alkaloid heteroside present in Solanum lycocarpum fruit. In addition solamargine was incorporated into nanoparticles (NP) of yttrium vanadate functionalized with 3-chloropropyltrimethoxysilane (YVO4:Eu3+:CPTES:SM) to determine antitumor activity. The anti-melanoma assessment was performed using a syngeneic mouse melanoma model B16F10 cell line. In addition, systemic toxicity, nephrotoxic, and genotoxic parameters were assessed. Solamargine, at doses of 5 or 10 mg/kg/day administered subcutaneously to male C57BL/6 mice for 5 days, decreased tumor size and frequency of mitoses in tumor tissue, indicative of a decrease in cell proliferation. Treatments with YVO4:Eu3+:CPTES:SM significantly reduced the number of mitoses in tumor tissue, associated with no change in tumor size. There were no apparent signs of systemic toxicity, nephrotoxicity, and genotoxicity initiated by treatments either with solamargine alone or plant alkaloid incorporated into NP. The animals treated with YVO4:Eu3+:CPTES:SM exhibited significant increase in spleen weight accompanied by no apparent histological changes in all tissues examined. In addition, animals treated with solamargine (10 mg/kg/day) and YVO4:Eu3+:CPTES:SM demonstrated significant reduction in hepatic DNA damage which was induced by tumor growth. Therefore, data suggest that solamargine may be considered a promising candidate in cancer therapy with no apparent toxic effects. (AU)

Processo FAPESP: 13/02744-7 - Potencial antitumoral e toxicológico da solamargina funcionalizada a nanopartículas de vanadato de ítrio
Beneficiário:Ricardo Andrade Furtado
Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 13/13903-9 - Avaliação das atividades genotóxica e antioxidante do extrato hidroalcoólico de Styrax camporum e dos seus marcadores químicos, egonol e homoegonol, e de sua influência sobre as lesões genômicas e pré-neoplásicas
Beneficiário:Denise Crispim Tavares Barbosa
Modalidade de apoio: Auxílio à Pesquisa - Regular
Processo FAPESP: 19/02641-0 - 6th Nano Today Conference
Beneficiário:Eduardo José Nassar
Modalidade de apoio: Auxílio à Pesquisa - Reunião - Exterior